山外山(688410.SH)：2022年度淨利預增182.44%-213.25%
格隆匯1月30日丨山外山(688410.SH)公佈，經公司財務部門初步測算，公司預計2022年年度實現營業收入3.6億元到4億元，與上年同期(法定披露數據)相比，將增加7672.00萬元到11,672.32萬元，同比上升27.08%到41.20%。
公司預計2022年年度實現歸屬於母公司所有者的淨利潤為5500.00萬元到6100.00萬元，與上年同期(法定披露數據)相比，將增加3552.67萬元到4152.67萬元，同比上升182.44%到213.25%。
公司預計 2022年年度歸屬於母公司所有者的扣除非經常性損益後的淨利潤為4200.00萬元到4700.00萬元，與上年同期(法定披露數據)相比，將增加2629.90萬元到3129.90萬元，同比上升167.50%到199.34%。
公司堅持自主研發技術創新，攻克關鍵核心技術，持續優化生產經營，強化成本管控，實現經營業績穩健提升，經營持續向好。
1、血液淨化設備：報吿期內，公司核心產品血液透析機和連續性血液淨化設備(CRRT)的銷量保持較快增長，營業收入增加。(1)國內市場：2022年度通過國產替代政策助力，依託品牌、技術優勢，將自研技術轉化提升市場份額，終端客户數量持續增加，預計銷售收入較上年同期保持較快增長；(2)國際市場：2022年度通過擴大銷售市場、原主要客户批量採購訂單、委託經銷商參展以及採用線上溝通交流等營銷方式，預計銷售收入較上年同期有穩定增長。
2、血液淨化耗材：在報吿期內，隨着公司自產耗材陸續上市和銷售市場的開拓，在銷售外購耗材和自產耗材方面都呈增長態勢。
3、連鎖血液透析中心：在報吿期內，通過提高品牌認可度和患者滿意度，預計營業收入較上年同期有所增長。
報吿期，公司預計歸屬於母公司所有者的非經常性損益影響歸屬於母公司所有者的淨利潤為1300萬元到1400萬元，主要系公司報吿期獲得的政府補助、理財收益所致。上年同期的歸屬於母公司所有者的非經常性損益金額為377.23萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
